PPRS

‘Free’ pricing in the UK: the influence of NICE and NHS England

https://pharmaphorum.com/views-and-analysis/pas-free-pricing-uk-nice-nhs-england/

NICE numbers: trends in recommendations should prompt a review of NICE

https://pharmaphorum.com/views-and-analysis/nice-numbers-trends-recommendations/

Has the UK been best place in the world to invest in life sciences?

https://pharmaphorum.com/views-and-analysis/uk-best-place-world-invest-life-sciences/

Could the PPRS support a changing growth and innovation agenda?

https://pharmaphorum.com/views-and-analysis/pprs-support-changing-growth-innovation-agenda/

Bureaucracy and duplication: the reality of the PPRS

https://pharmaphorum.com/views-and-analysis/bureaucracy-duplication-pprs/

Improved access? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/improved-access-reality-pprs/

What is ‘affordable’? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-impact-drug-budget/

Unstable and unpredictable? The reality of the PPRS

https://pharmaphorum.com/views-and-analysis/pprs-pharmaceutical-price-regulation-scheme/

The rise and fall of PPRS payments

https://pharmaphorum.com/views-and-analysis/rise-fall-pprs-payments/

1 2 3

Close in 10 seconds

Pharmaphorum.com

Search